{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:21:29Z","timestamp":1738218089354,"version":"3.34.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02590-4","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:31:40Z","timestamp":1736843500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PYGO2 promotes resistance to chemotherapy via reducing apoptosis and G2\/M cell cycle arrest in esophageal carcinoma cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Fatemeh","family":"Ardalan Moghadam Al","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-6897","authenticated-orcid":false,"given":"Mohammad Mahdi","family":"Forghanifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vajiheh","family":"Zarrinpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"6","key":"2590_CR1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","volume":"13","author":"DJ Uhlenhopp","year":"2020","unstructured":"Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010\u201321.","journal-title":"Clin J Gastroenterol"},{"issue":"3","key":"2590_CR2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","volume":"41","author":"FL Huang","year":"2018","unstructured":"Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210\u20135.","journal-title":"Asian J Surg"},{"issue":"2","key":"2590_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13402-019-00488-2","volume":"43","author":"A Fatehi Hassanabad","year":"2020","unstructured":"Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: towards targeted therapies. Cell Oncol (Dordr). 2020;43(2):195\u2013209.","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"2590_CR4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","volume":"154","author":"CC Abnet","year":"2018","unstructured":"Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360\u201373.","journal-title":"Gastroenterology"},{"issue":"1","key":"2590_CR5","volume":"341","author":"J Lagergren","year":"2010","unstructured":"Lagergren J, Lagergren P. Oesophageal cancer. BMJ. 2010;341(1): c6280.","journal-title":"BMJ"},{"issue":"10","key":"2590_CR6","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3390\/molecules13102370","volume":"13","author":"T Ito","year":"2008","unstructured":"Ito T, Tanabe K, Yamada H, Hatta H, Nishimoto S. Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors. Molecules. 2008;13(10):2370\u201384.","journal-title":"Molecules"},{"issue":"2","key":"2590_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115686","volume":"10","author":"C Focaccetti","year":"2015","unstructured":"Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE. 2015;10(2): e0115686.","journal-title":"PLoS ONE"},{"issue":"1","key":"2590_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijc.11176","volume":"106","author":"CN Arnold","year":"2003","unstructured":"Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003;106(1):66\u201373.","journal-title":"Int J Cancer"},{"issue":"4","key":"2590_CR9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000065068","volume":"62","author":"X Shi","year":"2002","unstructured":"Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002;62(4):354\u201362.","journal-title":"Oncology"},{"key":"2590_CR10","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/1078-0432.CCR-05-0769","volume":"14","author":"JL Grem","year":"2005","unstructured":"Grem JL. Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 2005;14:5067\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2590_CR11","first-page":"643","volume":"5","author":"B Van Triest","year":"1999","unstructured":"Van Triest B, Pinedo HM, Van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res. 1999;5(3):643\u201354.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2590_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ncb786","volume":"4","author":"B Thompson","year":"2002","unstructured":"Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol. 2002;4(5):367\u201373.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2590_CR13","first-page":"159","volume":"24","author":"I Esposito","year":"2020","unstructured":"Esposito I, Cassaro A. PYGO2 (pygopus family PHD finger 2). Atlas Genet Cytogenet Oncol Haematol. 2020;24(4):159\u201363.","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"issue":"10","key":"2590_CR14","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.7150\/jca.53356","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang D, Liu Y, Wu Q, Zheng Y, Kaweme NM, Zhang Z, et al. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. J Cancer. 2021;12(10):2952\u20139.","journal-title":"J Cancer"},{"key":"2590_CR15","first-page":"1","volume":"19","author":"C Zhou","year":"2020","unstructured":"Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/\u03b2-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes. Mol Cancer. 2020;19:1\u201324.","journal-title":"Mol Cancer"},{"issue":"2","key":"2590_CR16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12032-013-0516-9","volume":"30","author":"M Moghbeli","year":"2013","unstructured":"Moghbeli M, Abbaszadegan MR, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et al. Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol. 2013;30(2):516.","journal-title":"Med Oncol"},{"issue":"24","key":"2590_CR17","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1128\/MCB.00465-10","volume":"30","author":"J Chen","year":"2010","unstructured":"Chen J, Luo Q, Yuan Y, Huang X, Cai W, Li C, et al. Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol Cell Biol. 2010;30(24):5621\u201335.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2590_CR18","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3390\/cells9092125","volume":"9","author":"J Bian","year":"2020","unstructured":"Bian J, Dannappel M, Wan C, Firestein R. Transcriptional regulation of Wnt\/\u03b2-catenin pathway in colorectal cancer. Cells. 2020;9(9):2125.","journal-title":"Cells"},{"key":"2590_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/1471-2407-13-346","volume":"13","author":"Y Liu","year":"2013","unstructured":"Liu Y, Dong QZ, Wang S, Fang CQ, Miao Y, Wang L, et al. Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer. BMC Cancer. 2013;13:346.","journal-title":"BMC Cancer"},{"issue":"17","key":"2590_CR20","doi-asserted-by":"crossref","first-page":"27915","DOI":"10.18632\/oncotarget.15843","volume":"8","author":"C Zhou","year":"2017","unstructured":"Zhou C, Cheng H, Qin W, Zhang Y, Xiong H, Yang J, et al. Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells. Oncotarget. 2017;8(17):27915\u201328.","journal-title":"Oncotarget"},{"key":"2590_CR21","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1182\/blood-2023-181685","volume":"142","author":"NT Iannozzi","year":"2023","unstructured":"Iannozzi NT, Burroughs Garcia J, Marchica V, Franceschi V, Toscani D, Vescovini R, et al. PYGO2-MDR1 axis in multiple myeloma patients with 1q21 amplification as promising target to overcome carfilzomib resistance. Blood. 2023;142:6575.","journal-title":"Blood"},{"issue":"1","key":"2590_CR22","doi-asserted-by":"crossref","first-page":"e23625","DOI":"10.1002\/jbt.23625","volume":"38","author":"F Ardalan Moghadam Al","year":"2024","unstructured":"Ardalan Moghadam Al F, Forghanifard MM, Zarrinpour V. PYGO2 increases proliferation and migration capacities through critical signaling pathways in esophageal squamous cell carcinoma. J Biochem Mol Toxicol. 2024;38(1):e23625.","journal-title":"J Biochem Mol Toxicol."},{"issue":"8","key":"2590_CR23","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s12035-020-01922-5","volume":"57","author":"S Sahab-Negah","year":"2020","unstructured":"Sahab-Negah S, Ariakia F, Jalili-Nik M, Afshari AR, Salehi S, Samini F, et al. Curcumin loaded in niosomal nanoparticles improved the anti-tumor effects of free curcumin on glioblastoma stem-like cells: an in vitro study. Mol Neurobiol. 2020;57(8):3391\u2013411.","journal-title":"Mol Neurobiol"},{"key":"2590_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.","journal-title":"Mol Cancer"},{"issue":"3","key":"2590_CR25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/01478885.2019.1610214","volume":"42","author":"S Soleymani","year":"2019","unstructured":"Soleymani S, Khales SA, Jafarian AH, Kalat HR, Forghanifard MM. PYGO2 as an independent diagnostic marker expressed in a majority of colorectal cancers. J Histotechnol. 2019;42(3):98\u2013103.","journal-title":"J Histotechnol"},{"issue":"1","key":"2590_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12079-018-0476-0","volume":"13","author":"Y Liang","year":"2019","unstructured":"Liang Y, Wang C, Chen A, Zhu L, Zhang J, Jiang P, et al. Immunohistochemistry analysis of Pygo2 expression in central nervous system tumors. J Cell Commun Signal. 2019;13(1):75\u201384.","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"2590_CR27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12079-015-0314-6","volume":"10","author":"M Moghbeli","year":"2016","unstructured":"Moghbeli M, Sadrizadeh A, Forghanifard MM, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49\u201353.","journal-title":"J Cell Commun Signal"},{"issue":"49","key":"2590_CR28","doi-asserted-by":"crossref","first-page":"80612","DOI":"10.18632\/oncotarget.13016","volume":"7","author":"SB Talla","year":"2016","unstructured":"Talla SB, Brembeck FH. The role of Pygo2 for Wnt\/ss-catenin signaling activity during intestinal tumor initiation and progression. Oncotarget. 2016;7(49):80612\u201332.","journal-title":"Oncotarget"},{"key":"2590_CR29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27150","author":"LM van Tienen","year":"2017","unstructured":"van Tienen LM, Mieszczanek J, Fiedler M, Rutherford T, Bienz M. Correction: constitutive scaffolding of multiple Wnt enhanceosome components by legless\/BCL9. Elife. 2017. https:\/\/doi.org\/10.7554\/eLife.27150.","journal-title":"Elife"},{"issue":"1","key":"2590_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-020-01237-y","volume":"19","author":"C Zhou","year":"2020","unstructured":"Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/beta-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes. Mol Cancer. 2020;19(1):118.","journal-title":"Mol Cancer"},{"issue":"2","key":"2590_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/BC.2009.014","volume":"390","author":"D De","year":"2009","unstructured":"De D, Chen A, Wu Z, Lv S, He G, Qi Y. Overexpression of pygopus2 protects HeLa cells from vinblastine-induced apoptosis. Biol Chem. 2009;390(2):157\u201365.","journal-title":"Biol Chem"},{"issue":"36","key":"2590_CR32","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1038\/onc.2016.10","volume":"35","author":"ZM Zhang","year":"2016","unstructured":"Zhang ZM, Wu JF, Luo QC, Liu QF, Wu QW, Ye GD, et al. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt\/beta-catenin pathway. Oncogene. 2016;35(36):4787\u201397.","journal-title":"Oncogene"},{"issue":"23","key":"2590_CR33","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/onc.2009.80","volume":"28","author":"M Flahaut","year":"2009","unstructured":"Flahaut M, Meier R, Coulon A, Nardou K, Niggli F, Martinet D, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt\/\u03b2-catenin pathway. Oncogene. 2009;28(23):2245\u201356.","journal-title":"Oncogene"},{"issue":"9","key":"2590_CR34","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1111\/jcmm.14515","volume":"23","author":"Y Chi","year":"2019","unstructured":"Chi Y, Wang F, Zhang T, Xu H, Zhang Y, Shan Z, et al. miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2\/Wnt signalling pathway. J Cell Mol Med. 2019;23(9):6295\u2013307.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2590_CR35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/his.12637","volume":"67","author":"S Zhang","year":"2015","unstructured":"Zhang S, Li J, He F, Wang XM. Abnormal nuclear expression of Pygopus-2 in human primary hepatocellular carcinoma correlates with a poor prognosis. Histopathology. 2015;67(2):176\u201384.","journal-title":"Histopathology"},{"issue":"2","key":"2590_CR36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3892\/ol.2012.1014","volume":"5","author":"T Minegaki","year":"2013","unstructured":"Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K. Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett. 2013;5(2):427\u201334.","journal-title":"Oncol Lett"},{"issue":"8","key":"2590_CR37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/bjc.1998.617","volume":"78","author":"ME Nita","year":"1998","unstructured":"Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer. 1998;78(8):986\u20132.","journal-title":"Br J Cancer"},{"issue":"10","key":"2590_CR38","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1054\/bjoc.2000.1455","volume":"83","author":"JF Mirjolet","year":"2000","unstructured":"Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, et al. Bcl-2\/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer. 2000;83(10):1380\u20136.","journal-title":"Br J Cancer"},{"issue":"81","key":"2590_CR39","doi-asserted-by":"crossref","first-page":"eade4656","DOI":"10.1126\/sciimmunol.ade4656","volume":"8","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, et al. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci Immunol. 2023;8(81):eade4656.","journal-title":"Sci Immunol."},{"issue":"2","key":"2590_CR40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.oraloncology.2008.04.002","volume":"45","author":"S Yoshiba","year":"2009","unstructured":"Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol. 2009;45(2):109\u201315.","journal-title":"Oral Oncol"},{"issue":"1","key":"2590_CR41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1368-8375(03)00136-2","volume":"40","author":"MH Li","year":"2004","unstructured":"Li MH, Ito D, Sanada M, Odani T, Hatori M, Iwase M, et al. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol. 2004;40(1):63\u201370.","journal-title":"Oral Oncol"},{"issue":"9","key":"2590_CR42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1947601911432495","volume":"2","author":"LA Hoeferlin","year":"2011","unstructured":"Hoeferlin LA, Oleinik NV, Krupenko NI, Krupenko SA. Activation of p21-dependent G1\/G2 arrest in the absence of DNA damage as an antiapoptotic response to metabolic stress. Genes Cancer. 2011;2(9):889\u20139.","journal-title":"Genes Cancer"},{"key":"2590_CR43","volume":"12","author":"S Chen","year":"2022","unstructured":"Chen S, Li L. Degradation strategy of cyclin D1 in cancer cells and the potential clinical application. Front Oncol. 2022;12: 949688.","journal-title":"Front Oncol"},{"issue":"1","key":"2590_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2149039","volume":"23","author":"W Yuan","year":"2022","unstructured":"Yuan W, Zhao H, Zhou A, Wang S. Interference of EFNA4 suppresses cell proliferation, invasion and angiogenesis in hepatocellular carcinoma by downregulating PYGO2. Cancer Biol Ther. 2022;23(1):1\u201312.","journal-title":"Cancer Biol Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:36:11Z","timestamp":1738208171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["2590"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02590-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"45"}}